Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical trial.
机构:[1]Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China中山大学肿瘤防治中心[2]Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China临床科室内科中山大学肿瘤防治中心
Lin Tongyu,Sha Fushen,Huang He,et al.Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical trial.[J].JOURNAL OF CLINICAL ONCOLOGY.2018,36(15):-.doi:10.1200/JCO.2018.36.15_suppl.7553.
APA:
Lin, Tongyu,Sha, Fushen,Huang, He,Wang, Zhao,Lin, Suxia...&Liu, Qing.(2018).Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical trial..JOURNAL OF CLINICAL ONCOLOGY,36,(15)
MLA:
Lin, Tongyu,et al."Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical trial.".JOURNAL OF CLINICAL ONCOLOGY 36..15(2018):-